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Particle size is the major determinant in the deposition and distribution of inhaled drug within the lungs 14 
and hence is related to local efficacy . The particle size distribution of an aerosol is usually expressed in 15 
terms of its mass median aerodynamic diameter (MMAD). Particles deposit in the respiratory tract by 16 
inertial impaction (3-6µm), sedimentation (1-3µm) and diffusion ( <1µm). In order to reach the lower 17 
respiratory tract past the carina the MMAD of inhaled particles should be less than  5µm in diameter , 18 
specifically the particle size with the most efficient deposition in the small airways ,so called extra fine 19 
particle fraction is said to be <2um (1) . It has been demonstrated that smaller particles of inhaled 20 
salbutamol achieve greater overall lung deposition, along with greater peripheral lung distribution (2). 21 
Moreover smaller particles of long acting beta-agonist are also associated with improved small airways 22 
responses measured by impulse oscillometry (3).  23 
Whilst it is widely accepted that for efficient lung deposition, the MMAD should be lower than 5μm, it is 24 
more controversial what happens to small particles with MMAD lower than 1μm. It conventionally 25 
believed that, particles <1 µm are mainly exhaled and therefore may not able to elicit any therapeutic 26 
activity within the lungs, due to their extremely low settling velocity. Conversely, it could be argued that 27 
although small particles have a greater potential to be exhaled, this is counterpoised by their capability 28 
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to be distributed throughout the whole lungs and reach the distal airways with a high pulmonary 29 
deposition .We have therefore evaluated the relationship between in vitro MMAD and in vivo lung 30 
deposition (LD), and the exhaled fraction (EF) expressed as fraction of the delivered dose, using  pooled 31 
analysis from relevant literature using  scintigraphic studies conducted in healthy volunteers and 32 
asthmatic patients using pMDI or DPI. Moreover the relationship between the ratio of EF to LD and 33 
MMAD was also evaluated.  34 
We used pooled data (supplementary table) from 18 different  studies ,comprising 32 separate inhaled 35 
formulations , in healthy subjects (n=173) and asthmatics (n=124) ,21 formulations  in healthy 36 
volunteers, 15 with pressurised metered dose inhalers (pMDI) and 6 with dry powder inhalers (DPI); and 37 
11 formulations  in asthmatic patients, 8 with pMDI and 3 with DPI were evaluated. All participants were 38 
aged 18-65, and asthmatic patients had a mean FEV1 of 85% predicted, we combined the data in asthma 39 
patients with that of healthy volunteers. All subjects were non smokers .  40 
Lung deposition increased in relation to decreased MMAD, such that when the MMAD was around 1 µm 41 
the lung deposition exceeded 50% of the delivered dose and became markedly lower when MMAD 42 
approaches 4 µm (Figure 1a). Pointedly this pattern was similar in healthy and asthmatic patients. The 43 
exhaled fraction remained low irrespective of particle size. The mean amount of particles exhaled 44 
amounted to approximately 5 % of the emitted dose thus demonstrating that such extra fine particles 45 
are suitable for inhalation. Furthermore, the ratio of the amount exhaled to the amount deposited in 46 
the lung was found to be independent from the MMAD (Figure 1b).  47 
Our findings are consistent with previous data with inhaled salbutamol which similarly demonstrated 48 
that total lung deposition was greatest in particles with a MMAD of 1.5µm compared to particles of 3µm 49 
and 6µm (4). It could be argued that the ability to correctly perform the inhalation including an 50 
adequate breath-holding is likely to decrease the amount of exhaled drug. In this regard in all of the 51 
included studies in our cohort , inhaler technique with a given device was standardised .Previous data(5) 52 
have demonstrated that extra-fine particles are able to reach the small airways more effectively and 53 
hence achieve better drug distribution throughout the whole bronchial tree. Interestingly they also 54 
indicate that the exhaled fraction is approximately 12 % of the dose deposited in the lung and is totally 55 
independent from the MMAD further confirming that extra-fine particles are suitable for inhalation. The 56 
clinical relevance of extra-fine particles <2um  has been demonstrated by Nicolini and colleagues (6) 57 
who compared extra-fine (MMAD 1.1um)  versus coarse particle HFA-beclometasone (MMAD 3.5um) , 58 
in individuals with asthma, and demonstrated the extra-fine particles significantly reduced both 59 
3 
bronchial and alveolar exhaled nitric oxide unlike coarse particle, which only reduced bronchial exhaled 60 
nitric oxide. Moreover, extra-fine HFA-flunisolide (MMAD 1.2um) has been shown to reduce histological 61 
evidence of eosinophilic and interleukin 5 mediated inflammation in peripheral and central airways after 62 
6 weeks of treatment (7). If these extra-fine particles were mostly exhaled, as conventionally believed, 63 
one would not expect there to be an improvement in small airway inflammation as evidenced invasively 64 
and non-invasively. It should be appreciated that there will be a normal distribution of particle size 65 
around the MD ,such with an MMAD of 1.1um there will be a proportion of particles <1um. In this 66 
regard such smaller particles may be absorbed from the alveoli and potentially increase systemic 67 
adverse effects , although such alveolar deposition might also contribute to anti-asthmatic efficacy as 68 
shown in association with the nocturnal phenotype (8). Our asthma cohort of asthma patients had an 69 
FEV1 of 85% predicted, in this regard it has been shown that there is  evidence of small airways 70 
dysfunction in terms of a raised peripheral airways resistance occurring in approximately of half of 71 
patients who have  a preserved FEV1 >80% predicted (9). 72 
In summary the present data demonstrate that the EF/LD ratio is independent from the MMAD, 73 
suggesting that extra-fine particles will not be associated with an appreciably higher exhaled fraction. 74 
Further prospective studies are required to assess how this relates to clinical efficacy in patients with 75 
more severe asthma, perhaps using   impulse oscillometry to better assesses the small airways (10).  76 
77 
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Does size really matter- relationship of particles size to lung deposition and exhaled fraction. 
Figure 1.a 
Pooled data from 18 different studies, comprising 32 separate inhaled formulations, each point represents a 
particular formulation. Lung deposition (circles) and Exhaled drug (squares) as function of MMAD (µm). 
Regression line and the 95% confidence intervals are also shown. 
Figure 1.b 
Ratio of Exhaled vs lung deposited drug as function of MMAD (µm).  Regression line and the 95% confidence 
intervals are also shown. 
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Full triangles: healthy volunteers 
Open triangles: asthmatic patients 
Figure 1.a 
Lung deposition (circles) and Exhaled drug (squares) as function of MMAD (µm). Regression line and the 95% 
confidence intervals are also shown. 
Formatted: Justified, Line spacing: 
1.5 lines
Figure No.1 - Marked
Figure 1.a 
Pooled data from 18 different studies, comprising 32 separate inhaled formulations, each point represents a particular 
formulation. Lung deposition (circles) and Exhaled drug (squares) as function of MMAD (µm). Regression line and the 
95% confidence intervals are also shown. 
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Figure 1.b 
Ratio of Exhaled vs lung deposited drug as function of MMAD (µm).  Regression line and the 95% confidence intervals 
are also shown. 
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